Rheumatic Heart Disease Clinical Trial
Official title:
Prevalence of Rheumatic Heart Disease in Zambian Schoolchildren: an Echocardiographic Screening Study Involving Task-shifting to General Radiographers
This study will determine the prevalence of rheumatic heart disease (RHD) in Lusaka, Zambia through school-based screening methodology using ultraportable echocardiography and a recently validated, abridged screening protocol based on World Heart Federation criteria. Children that screen positive for RHD at schools will undergo confirmatory evaluation at University Teaching Hospital (UTH), Lusaka's main referral hospital.
It has been estimated that RHD affects over 32 million people worldwide, with the vast
majority of cases occurring in the developing world. RHD is the most common cardiovascular
disease in children and young adults and is a major cause of death in children above the age
of 5 in many parts of the developing world, particularly sub-Saharan Africa.
RHD results from repeated attacks of acute rheumatic fever (ARF). ARF is a systemic
inflammatory disease occurring mainly in children, characterized by fever, painful joints,
and heart, skin, and neurological manifestations. ARF is linked with preceding Group A
streptococcal (GAS) throat infections, which, if left untreated, carry an estimated 2-3%
risk of developing ARF.
The pathologic hallmark of RHD is classically a valvulitis that affects mostly the mitral
and/or aortic valves. Inflammation of the myocardium and pericardium may exacerbate the
effects of valvular insufficiency, resulting in congestive heart failure, stroke and other
complications. Over time, severe disability or death can ensue, especially in developing
countries where the management of RHD patients is challenging and surgical interventions are
not readily available.
ARF and RHD are diseases of poverty, especially in countries with limited healthcare
systems. GAS thrives in situations of over-crowding where poor nutrition and sanitation are
common and where medical treatment for sore throat is not readily available. For these
reasons, RHD is endemic in many parts of the developing world, particularly sub-Saharan
Africa, while it almost disappeared from most parts of the developed world (except for
indigenous populations in some countries). It should be noted that the initial decline of
ARF/RHD in the US and Europe most likely was due to improved living conditions and hygiene
(primordial prevention), since it predated the introduction of penicillin.
RHD is one of few truly preventable chronic diseases. Currently, many sub-Saharan African
countries do not focus efforts on primary and secondary prevention due to lack of resources.
The long-term goal of an ongoing effort in Zambia is to develop capability to provide
effective primary and secondary prevention of RHD, with the ultimate goal of eliminating new
cases.
Although RHD is associated with major morbidity and mortality in children and young adults,
until recently few reliable estimates of the burden from this disease existed in sub-Saharan
Africa. Population-based screening for RHD had been limited to clinical examination, which
does not detect early RHD in which a heart murmur or other clinical signs of disease are
absent (subclinical disease). Estimates of RHD prevalence based on clinical surveillance
methods compared with screening echocardiography have been shown to result in gross
underestimates (up to 10 fold).
With advances in portable ultrasonography and the development of international guidelines
for echocardiographic diagnosis of RHD, population-based screening for subclinical RHD is
now possible. Using this new approach, recent studies in countries with similar geographic
and demographic profiles to Zambia showed that RHD prevalence in sub-Saharan Africa is much
higher than previously thought; approximately 1-3% of schoolgoing children appear to have
evidence of definite or borderline RHD.
In this study, the investigators will apply echocardiographic screening methods to determine
the prevalence of RHD in a large population of Zambian school children. Data on the disease
burden of RHD in Zambia will be used to inform the design and conduct of health programs to
combat RHD.
The proposed study will involve a sample size of at least 1,024 students in grades 7-12 in
fifteen randomly selected schools in Lusaka. Each student that meets inclusion criteria will
undergo a focused history and physical examination and rapid echocardiographic screening.
The fifteen schools involved in the study will be identified as a random sample from 119
currently operating primary and secondary schools in Lusaka using standard sampling methods.
Approximately 60-80 students from each school will be screened. The screening will be
conducted using an ultraportable ultrasound device and an abridged screening protocol that
has been validated in a separate study by investigators at the University of Cape Town in
South Africa. Children with suspected ARF or RHD will be followed up at UTH for an in-depth
clinical examination and quantitative electrocardiogram. Children with definite or
borderline RHD according to World Heart Federation Criteria will be offered secondary
penicillin prophylaxis according to national guidelines in Zambia. Children with sore throat
will be referred for evaluation and treatment with penicillin according to national
guidelines for primary prevention of RHD at UTH or a local health clinic.
An additional feature of this study is the development of local technical expertise to
conduct echocardiographic screening. This is necessary because few health workers in Lusaka
are proficient in cardiac echocardiography. The feasibility of task-shifting
echocardiographic screening to non-expert health workers has been demonstrated in similar
settings. The investigators will therefore train radiography technicians who have little or
no previous experience with echocardiography to conduct school-based screening.
Given that radiographers will be newly trained to conduct screening echocardiography, two
mechanisms will be implemented to help ensure successful school screening: (1) international
echocardiography technician experts will periodically accompany study staff during school
screenings to support the work of local radiographers; and (2) all screening echocardiograms
will be de-identified and reviewed remotely by a professional third-party echocardiographer
who will report back on any echocardiograms that are determined to be read as falsely
negative by the field team.
Most data that will be obtained for the study will be entered through mobile electronic
devices (computer tablets) at the time of capture into a digital system ("eRegister") that
will be developed specifically for the study. The system uses DiMagi's "CommCare" platform,
which includes a customizable mobile health data collection application and an online
portal, "CommCareHQ," for secure data viewing and reporting. All access to the CommCare
platform including mobile submissions will be done over HTTPS (hypertext transfer protocol)
and will be cryptographically secure. Mobile devices will be password-locked and accessible
only by the study staff member to whom the device is allocated. Once data are submitted to
the server they will be automatically erased from the mobile device. Echocardiograms will
also be saved in the system; images and videos will be temporarily stored on the hard drive
of the ultrasound device and then transferred to the eRegister.
;
Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05991219 -
Screening and Secondary Prevention Rheumatic Heart Disease Study
|
||
Completed |
NCT02188862 -
Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region
|
N/A | |
Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A | |
Recruiting |
NCT05693545 -
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
|
Phase 2 | |
Completed |
NCT06150274 -
Comparison of Wire Assisted Percutaneous Balloon Mitral Valvulotomy With Standard Inoue Balloon Valvulotomy
|
N/A | |
Terminated |
NCT03926156 -
RIvoraxaban in Mitral Stenosis
|
Phase 3 | |
Recruiting |
NCT05783375 -
Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda
|
N/A | |
Completed |
NCT02474108 -
Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement
|
N/A | |
Recruiting |
NCT04556188 -
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
|
||
Recruiting |
NCT03991910 -
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients
|
Phase 3 | |
Active, not recruiting |
NCT03346525 -
Determining the Impact of Penicillin in Latent RHD: The GOAL Trial
|
Phase 2 | |
Recruiting |
NCT05504928 -
Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease
|
N/A | |
Not yet recruiting |
NCT03549052 -
Right Ventricular Echo Assessment in Mitral Valve Replacement
|
||
Recruiting |
NCT05487469 -
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT05276999 -
Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET"
|
N/A | |
Completed |
NCT05668611 -
Train the Trainer Curriculum to Scale up AI Supported Echo for RHD Screening in a Public Health System
|
N/A | |
Active, not recruiting |
NCT05211024 -
A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
|
||
Withdrawn |
NCT02832531 -
INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
|
Phase 3 | |
Completed |
NCT01794884 -
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery
|
Phase 2 | |
Completed |
NCT00264524 -
DNA Typing of HLA-DR/DQ Alleles in Taiwan Chinese With Rheumatic Heart Disease
|
N/A |